REFERENCES
1. Fuster-Lluch O, Geronimo-Pardo M, Peyro-Garcia R, Lizan-Garcia M. Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesthesia and intensive care 2008; 36: 674-80.
2. Udy AA, Jarrett P, Lassig-Smith M, Stuart J, Starr T, Dunlop R, Deans R, Roberts JA, Senthuran S, Boots R. Augmented renal clearance in traumatic brain injury: a single-center observational study of atrial natriuretic peptide, cardiac output, and creatinine clearance. Journal of neurotrauma 2017; 34: 137-44.
3. Conil J, Georges B, Lavit M, Seguin T, Tack I, Samii K, Chabanon G, Houin G, Saivin S. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance. International journal of clinical pharmacology and therapeutics 2007; 45: 529-38.
4. Mahmoud SH, Shen C. Augmented renal clearance in critical illness: an important consideration in drug dosing. Pharmaceutics 2017; 9: 36.
5. Ruiz S, Minville V, Asehnoune K, Virtos M, Georges B, Fourcade O, Conil J-M. Screening of patients with augmented renal clearance in ICU: taking into account the CKD-EPI equation, the age, and the cause of admission. Annals of intensive care 2015; 5: 49.
6. Claus BO, Hoste EA, Colpaert K, Robays H, Decruyenaere J, De Waele JJ. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. Journal of critical care 2013; 28: 695-700.
7. Cook AM, Hatton‐Kolpek J. Augmented renal clearance. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2019; 39: 346-54.
8. Carrie C, Bentejac M, Cottenceau V, Masson F, Petit L, Cochard J-F, Sztark F. Association between augmented renal clearance and clinical failure of antibiotic treatment in brain-injured patients with ventilator-acquired pneumonia: a preliminary study. Anaesthesia Critical Care & Pain Medicine 2018; 37: 35-41.
9. Conil J-M, Georges B, Mimoz O, Dieye E, Ruiz S, Cougot P, Samii K, Houin G, Saivin S. Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients. Intensive care medicine 2006; 32: 2063-66.
10. De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M, Koulenti D, Martin C, Montravers P, Rello J. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients. Intensive care medicine 2014; 40: 1340-51.
11. Wu C-C, Tai C-H, Liao W-Y, Wang C-C, Kuo C-H, Lin S-W, Ku S-C. Augmented renal clearance is associated with inadequate antibiotic pharmacokinetic/pharmacodynamic target in Asian ICU population: a prospective observational study. Infection and drug resistance 2019; 12: 2531.
12. Ohata Y, Tomita Y, Nakayama M, Tamura K, Tanigawara Y. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic–pharmacodynamic analysis. Journal of Infection and Chemotherapy 2011; 17: 831-41.
13. Kees MG, Minichmayr IK, Moritz S, Beck S, Wicha SG, Kees F, Kloft C, Steinke T. Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients. Journal of clinical pharmacology 2016; 56: 307-15.
14. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008; 47 Suppl 1: S32-40.
15. Taccone FS, Laterre P-F, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent J-L, Jacobs F. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Critical Care 2010; 14: R126.
16. Jaruratanasirikul S, Sriwiriyajan S. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. The Journal of antimicrobial chemotherapy 2003; 52: 518-21.
17. Yu Z, Pang X, Wu X, Shan C, Jiang S. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis. PloS one 2018; 13.
18. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infectious Disease Clinics 2003; 17: 479-501.
19. Udy AA, Roberts JA, Shorr AF, Boots RJ, Lipman J. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Critical Care 2013; 17: R35.
20. Elkhaïli H, Niedergang S, Pompei D, Linger L, Leveque D, Jehl F. High-performance liquid chromatographic assay for meropenem in serum. Journal of Chromatography B: Biomedical Sciences and Applications 1996; 686: 19-26.
21. Carlier M, Carrette S, Roberts JA, Stove V, Verstraete A, Hoste E, Depuydt P, Decruyenaere J, Lipman J, Wallis SC. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Critical care 2013; 17: R84.
22. Ehmann L, Zoller M, Minichmayr IK, Scharf C, Maier B, Schmitt MV, Hartung N, Huisinga W, Vogeser M, Frey L. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study. Critical care 2017; 21: 263.
23. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen K-M, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, Study D, Roberts JA, Lipman J, Starr T, Wallis SC, Paul SK, Margarit Ribas A, De Waele JJ, De Crop L, Spapen H, Wauters J, Dugernier T, Jorens P, Dapper I, De Backer D, Taccone FS, Rello J, Ruano L, Afonso E, Alvarez-Lerma F, Gracia-Arnillas MP, Fernández F, Feijoo N, Bardolet N, Rovira A, Garro P, Colon D, Castillo C, Fernado J, Lopez MJ, Fernandez JL, Arribas AM, Teja JL, Ots E, Carlos Montejo J, Catalan M, Prieto I, Gonzalo G, Galvan B, Blasco MA, Meyer E, Del Nogal F, Vidaur L, Sebastian R, Garde PM, Martin Velasco MdM, Zaragoza Crespo R, Esperatti M, Torres A, Montravers P, Baldesi O, Dupont H, Mahjoub Y, Lasocki S, Constantin JM, Payen JF, Martin C, Albanese J, Malledant Y, Pottecher J, Lefrant J-Y, Jaber S, Joannes-Boyau O, Orban C, Ostermann M, McKenzie C, Berry W, Smith J, Lei K, Rubulotta F, Gordon A, Brett S, Stotz M, Templeton M, Rhodes A, Ebm C, Moran C, Kaukonen K-M, Pettilä V, Dimopoulos G, Koulenti D, Xristodoulou A, Theodorou V, Kouliatsis G, Sertaridou E, Anthopoulos G, Choutas G, Rantis T, Karatzas S, Balla M, Papanikolaou M, Myrianthefs P, Gavala A, Fildisis G, Koutsoukou A, Kyriakopoulou M, Petrochilou K, Kompoti M, Michalia M, Clouva-Molyvdas F-M, Gkiokas G, Nikolakopoulos F, Psychogiou V, Malliotakis P, Akoumianaki E, Lilitsis E, Koulouras V, Nakos G, Kalogirou M, Komnos A, Zafeiridis T, Chaintoutis C, Arvaniti K, Matamis D, Chaintoutis C, Kydona C, Gritsi-Gerogianni N, Giasnetsova T, Giannakou M, Soultati I, Chytas I, Antoniadou E, Antipa E, Lathyris D, Koukoubani T, Paraforou T, Spiropoulou K, Bekos V, Spring A, Kalatzi T, Nikolaou H, Laskou M, Strouvalis I, Aloizos S, Kapogiannis S, Soldatou O, Bassetti M, Adembri C, Villa G, Giarratano A, Maurizio Raineri S, Cortegiani A, Montalto F, Strano MT, Ranieri VM, Sandroni C, De Pascale G, Molin A, Pelosi P, Montagnani L, Urbino R, Mastromauro I, De Rosa FG, Ranieri VM, Cardoso T, Afonso S, Gonçalves-Pereira J, Baptista JP, Akova M, Özveren A. DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β-Lactam Antibiotic Doses Sufficient for Critically Ill Patients? Clinical Infectious Diseases 2014; 58: 1072-83.
24. Li C, Du X, Kuti JL, Nicolau DP. Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections. Antimicrobial Agents and Chemotherapy 2007; 51: 1725-30.
25. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (<em>T</em>&gt;MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. International Journal of Antimicrobial Agents 2008; 31: 345-51.
26. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem. Drugs 1995; 50: 73-101.
27. Mattioli F, Fucile C, Del Bono V, Marini V, Parisini A, Molin A, Zuccoli ML, Milano G, Danesi R, Marchese A, Polillo M, Viscoli C, Pelosi P, Martelli A, Di Paolo A. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. European journal of clinical pharmacology 2016; 72: 839-48.
28. Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Critical Care 2011; 15: R206.
29. Petersson J, Giske C, Eliasson E. Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients. Acta Anaesthesiologica Scandinavica 2016; 60: 1425-36.
30. Tröger U, Drust A, Martens-Lobenhoffer J, Tanev I, Braun-Dullaeus RC, Bode-Böger SM. Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring. International Journal of Antimicrobial Agents 2012; 40: 370-72.
31. Kothekar AT, Divatia JV, Myatra SN, Patil A, Krishnamurthy MN, Maheshwarappa HM, Siddiqui SS, Gurjar M, Biswas S, Gota V. Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria. Annals of Intensive Care 2020; 10: 4.
Table 1. The ARC risk scoring systems [4]